Amneal Wins Generics Bulletin "Company of The Year" Award
Leading generics maker is recognized for exceptional growth.
Bridgewater, NJ (USA), October 21, 2014 — Amneal Pharmaceuticals LLC is pleased to announce that the company has won the global “Company of the Year - Americas” Award from Generics bulletin, a newsletter which provides commercial and regulatory information for the global generics and biosimilars industries. Presented on October 7 at the Global Generics & Biosimilars Awards 2014 held in Paris, France, the award recognizes Amneal’s rapid growth in North America.
Amneal is the 7th largest U.S. generics manufacturer based on prescriptions dispensed, according to IMS Health. The company’s 76 FDA-approved generic medications and robust pipeline of 264 products filed with the U.S. FDA or in development cover a broad range of therapeutic categories. In addition to high-volume commodity medicines, Amneal’s portfolio contains many high-barrier-to-entry and difficult-to-formulate products and spans almost the entire range of dosage forms in the market.
To produce the highest quality generic medications for its customers and accelerate its incredible growth, Amneal is making major investments in research and development, infrastructure, and human capital. The company will spend more than $400 million on R&D and capital improvements to its nine manufacturing plants in the U.S. and India over the next two years. Amneal has also invested considerable resources in human capital as well as product development and now employs over 2,600 worldwide.
In addition to its U.S. operations, Amneal is expanding internationally by establishing front-end marketing and distribution capabilities in UK, Spain, Germany, the Nordic countries, Switzerland, and Australia. The company is also pursuing acquisitions and evaluating strategic partners in Japan, Southeast Asia, and Latin America.
“We are deeply honored to be recognized as ‘Company of the Year for the Americas’,” said Amneal Co-CEO and Co-Chairman Chirag Patel. “This award lets us know we’re doing all the right things to run a successful, growing enterprise while remaining true to our values - dedication to quality across all operations, maintaining our high standards and ethics and total commitment to our customers, partners and employees.”
The news was also featured in the October 17 issue of Generics bulletin at https://www.generics-bulletin.com/media/8807/generics-bulletin-17-10-14-fc.jpg.
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC is a U.S.-based manufacturer of generic pharmaceuticals. Known as “Generic's New Generation®”, Amneal prides itself on its unwavering commitment to quality, meaningful business relationships, and its innovative approach to maximizing value for all stakeholders. Extensive investment in R&D, an intelligently aggressive expansion strategy, and focus on vertical integration are key contributors to the company’s impressive growth over the past several years. Amneal is headquartered in Bridgewater, New Jersey with manufacturing, R&D, packaging, sales and distribution facilities throughout the U.S. as well as abroad. For more information, visit www.amneal.com.
Jim Luce Cheryl Lechok
Executive Vice President, Sales & Marketing President
Amneal Pharmaceuticals LLC Cheryl Lechok Communications, LLC
M: 949.500.5756 Dir: 203-961-9280
firstname.lastname@example.org M: 203-613-1506